Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF | V.TLT.W

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Post by Claridgeon Oct 11, 2019 1:52pm
194 Views
Post# 30222881

Dr. Lilge's other project

Dr. Lilge's other projectDr. Lilge's other project ... The impatients on this board will see that oncology R&D takes time.

He's mentioned in this 2019-10-03 article




In 2004, Dr. Lilge was behind this paper:





In 2008, Dr. Lilge was a lead author on this paper:



In 2017,Dr.Lilge came up with this light-based technology:


Lothar Lilge
 
added an update
Analysis of Young women/girls undergoing puberty based on the Toronto cohort measured with a full spectral content 630 to 1060 nm
… 



And this research topic dates back @UHN to 2007:

2007 - UHN study Identifies Breast Density as the #1 Risk Factor for Breast Cancer

Bullboard Posts